Our findings show that AGO can attenuate the depressive-like behavior that significantly appeared in both sucrose preference and forced swimming tests. Meanwhile, the expression of the BDNF/TrkB/pERK signaling pathway, apoptosis, autophagy, and inflammatory protein markers were assessed using western blot and immunofluorescence. The number of behavioral tests was conducted to evaluate the effect of AGO on depression-like behavior alleviation. The CRS model mice were established in 28 days with AGO (60 mg/kg/day, by oral) or fluoxetine (15 mg/kg/day, by oral) administration. In this study, we sought to evaluate the antidepressant effects of AGO on the chronic restraint stress (CRS) mouse model and preliminarily investigate its effects on the gut microbial metabolites. However, its effects and the underlying mechanism are still unclear. Agomelatine (AGO) was reported as an antidepressant with unique pharmacological effects. Searching for more effective treatments for depression is a long-standing primary objective in neuroscience. Depression is a common and disabling mental disorder with high recurrence rate.
0 kommentar(er)
